Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

Oxford Immunotec Global PLC , a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT .

http://ift.tt/16tmyAm